{"schema_version":"1.0","type":"article","title":"信達的全球化列車，台灣的圓祥搭上了？","url":"https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.md","lang":"zh-Hant","date":"2026-04-01","publish_at":"2026-04-01T10:30:00+08:00","updated_at":"2026-04-01","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","BD","臨床數據","生技投資"],"summary":"3 月 24 日，信達生物公布 efdamrofusp alfa（IBI302） 在中國新生血管型老年黃斑部病變（nAMD）關鍵三期 STAR 試驗達成 52 週主要終點。乍看之下，這像是一則典型的臨床里程碑新聞；但若把它放回全球眼科產業的競爭結構裡看，這件事的重要性遠不只是一款新藥在單一市場報捷。","key_points":[],"facts":[],"sections":["當 IBI302 三期達標，信達與圓祥真正想拿下的，不只是中國藥證","IBI302 的關鍵，不只是達標，而是它想改寫下一代眼底藥的競爭邏輯","這不是只在中國對標 Eylea，而是開始往全球下一代眼科賽道卡位","對圓祥而言，這不只是臨床好消息，而是國際授權談判桌上的硬籌碼","信達現在要做的，不只是多一支眼科藥，而是建立整條眼科平台","國際藥廠已經不再只把信達當中國公司看待","這次 STAR 成功，其實一次回答了三個問題","結語：真正的分水嶺，不是藥證，而是它開始改變整個產業算盤"],"references":[],"images":[{"alt":"Dcard 原圖：信達的全球化列車，台灣的圓祥搭上了？（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261215001/dcard-01.webp"},{"alt":"Dcard 原圖：信達的全球化列車，台灣的圓祥搭上了？（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261215001/dcard-02.webp"},{"alt":"Dcard 原圖：信達的全球化列車，台灣的圓祥搭上了？（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261215001/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261215001/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-01）。信達的全球化列車，台灣的圓祥搭上了？。https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-01-dcard-261215001-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}